US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Oncolytics Biotech Inc. - Common Stock
(NQ:
ONCY
)
0.4254
-0.0023 (-0.54%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncolytics Biotech Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers
October 14, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 14, 2021 – USA News Group – Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3...
Via
FinancialNewsMedia
Topics
Stocks
Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments
October 14, 2021
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend...
Via
FinancialNewsMedia
Oncolytics Biotech® Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
October 14, 2021
Trial is designed to advance pelareorep’s clinical development in China, the world’s second-largest pharmaceutical market San Diego, CA and Calgary, AB – October 14, 2021 — Oncolytics Biotech® Inc....
Via
FinancialNewsMedia
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
September 20, 2021
Via
FinancialNewsMedia
Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer
↗
May 20, 2021
Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: ...
Via
Benzinga
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
May 20, 2021
Via
FinancialNewsMedia
Topics
Death
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
September 20, 2021
Via
FinancialNewsMedia
Oncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer
↗
April 12, 2021
Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study...
Via
Benzinga
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
↗
April 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc...
Via
Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
↗
August 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Earnings Scheduled For August 6, 2021
↗
August 06, 2021
Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million....
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
↗
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
↗
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
55 Biggest Movers From Yesterday
↗
April 13, 2021
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with...
Via
Benzinga
51 Biggest Movers From Friday
↗
April 12, 2021
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
